Skip to main content

Advertisement

SpringerLink
Log in

Managing the risks of IBD therapy

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression. A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination). One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of ineffective therapies mandating urgent review. Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ng SC, Kamm MA: Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009, 15:935–950.

    Article  PubMed  Google Scholar 

  2. Lichtenstein GR, Hanauer SB, Sandborn WJ: Management of Crohn’s disease in adults. Am J Gastroenterol 2009, 104:465–483; quiz 464, 484.

    Article  PubMed  Google Scholar 

  3. Das KM, Eastwood MA, McManus JP, et al.: Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973, 289:491–495.

    Article  CAS  PubMed  Google Scholar 

  4. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004, 99:1371–1385.

    Article  PubMed  Google Scholar 

  5. Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632.

    Article  CAS  PubMed  Google Scholar 

  6. Benchimol EI, Seow CH, Steinhart AH, et al.: Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008:CD006792.

  7. Steinhart AH, Ewe K, Griffiths AM, et al.: Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003:CD000301.

  8. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621–630.

    Article  CAS  PubMed  Google Scholar 

  9. Lal S, Steinhart AH: Antibiotic therapy for Crohn’s disease: a review. Can J Gastroenterol 2006, 20:651–655.

    PubMed  Google Scholar 

  10. Van Assche G, Vermeire S, Rutgeerts P: Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008, 10:591–596.

    Article  PubMed  Google Scholar 

  11. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005, 353:1912–1925.

    Article  CAS  PubMed  Google Scholar 

  12. US Food and Drug Administration: Natalizumab Injection for Intravenous Use: 2008. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrug-LabelingChanges/ucm106674.htm. Accessed September 2009.

  13. Duffy LF, Daum F, Fisher SE, et al.: Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 1985, 88:681–684.

    CAS  PubMed  Google Scholar 

  14. Fromont A, De Seze J, Fleury MC, et al.: Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55–57.

    Article  CAS  PubMed  Google Scholar 

  15. Tysabri [prescribing information]. Available at http://www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed October 2009.

  16. Seow CH, Benchimol EI, Griffiths AM, et al.: Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008:CD000296.

  17. Lichtenstein GR, Sands BE, Pazianas M: Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:797–813.

    Article  PubMed  Google Scholar 

  18. American Gastroenterological Association: Medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791–794.

    Article  Google Scholar 

  19. Cunliffe RN, Scott BB: Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:647–662.

    Article  CAS  PubMed  Google Scholar 

  20. Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:961–968.

    CAS  PubMed  Google Scholar 

  21. Wagnon JH, Leiman DA, Ayers GD, et al.: Survey of gastroenterologists’ awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm Bowel Dis 2009, 15:1082–1089.

    Article  PubMed  Google Scholar 

  22. Garcia-Moran S, Saez-Royuela F, Perez-Alvarez JC, et al.: Myopericarditis and mitral insufficiency associated with ulcerative colitis treated with mesalazine. Inflamm Bowel Dis 2006, 12:334–335.

    Article  PubMed  Google Scholar 

  23. Chung ES, Packer M, Lo KH, et al.: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133–3140.

    Article  CAS  PubMed  Google Scholar 

  24. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al.: TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005, 4:153–161.

    Article  CAS  PubMed  Google Scholar 

  25. Camus P, Bonniaud P, Fanton A, et al.: Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004, 25:479–519, vi.

    Article  PubMed  Google Scholar 

  26. Gisbert JP, Gonzalez-Lama Y, Mate J: 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007, 13:629–638.

    Article  PubMed  Google Scholar 

  27. Elseviers MM, D’Haens G, Lerebours E, et al.: Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol 2004, 61:83–89.

    CAS  PubMed  Google Scholar 

  28. de Jong DJ, Tielen J, Habraken CM, et al.: 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 2005, 11:972–976.

    Article  PubMed  Google Scholar 

  29. World MJ, Stevens PE, Ashton MA, et al.: Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996, 11:614–621.

    CAS  PubMed  Google Scholar 

  30. Jobanputra P, Amarasena R, Maggs F, et al.: Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008, 9:48.

    Article  PubMed  Google Scholar 

  31. Vernier-Massouille G, Cosnes J, Lemann M, et al.: Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007, 56:1404–1409.

    Article  CAS  PubMed  Google Scholar 

  32. Dominique L: Liver toxicity of TNFalpha antagonists. Joint Bone Spine 2008, 75:636–638.

    Article  PubMed  Google Scholar 

  33. Bermejo F, Lopez-Sanroman A, Taxonera C, et al.: Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008, 28:623–628.

    Article  CAS  PubMed  Google Scholar 

  34. Saag KG, Teng GG, Patkar NM, et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762–784.

    Article  CAS  PubMed  Google Scholar 

  35. Te HS, Schiano TD, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150–3156.

    Article  CAS  PubMed  Google Scholar 

  36. Jick H, Myers MW, Dean AD: The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy 1995, 15:176–181.

    CAS  PubMed  Google Scholar 

  37. Connell WR, Kamm MA, Ritchie JK, et al.: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081–1085.

    Article  CAS  PubMed  Google Scholar 

  38. Gisbert JP, Gomollon F, Cara C, et al.: Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007, 52:1262–1269.

    Article  CAS  PubMed  Google Scholar 

  39. Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005, 20:1149–1157.

    Article  CAS  PubMed  Google Scholar 

  40. Exarchou S, Voulgari P, Markatseli T, et al.: Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009:1–4.

  41. Wollina U, Hansel G, Koch A, et al.: Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1–14.

    Article  PubMed  Google Scholar 

  42. Michel F, Navellou JC, Ferraud D, et al.: DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. Joint Bone Spine 2005, 72:82–85.

    Article  PubMed  Google Scholar 

  43. D’Haens G, Columbel JF, Hommes D, et al.: Corticosteroids pose an increased risk of serious infection: An interim safety analysis of the ENCORE registry. Gastroenterol 2008, 134:A946.

    Google Scholar 

  44. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.

    Article  CAS  PubMed  Google Scholar 

  45. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476.

    Article  CAS  PubMed  Google Scholar 

  46. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65.

    Article  CAS  PubMed  Google Scholar 

  47. Toruner M, Loftus EV Jr, Harmsen WS, et al.: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929–936.

    Article  PubMed  Google Scholar 

  48. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098–1104.

    Article  CAS  PubMed  Google Scholar 

  49. Raval A, Akhavan-Toyserkani G, Brinker A, et al.: Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007, 147:699–702.

    PubMed  Google Scholar 

  50. Mow WS, Abreu-Martin MT, Papadakis KA, et al.: High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004, 2:309–313.

    Article  PubMed  Google Scholar 

  51. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766–1772.

    Article  CAS  PubMed  Google Scholar 

  52. D’Ovidio V, Vernia P, Gentile G, et al.: Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008, 43:180–183.

    Article  PubMed  CAS  Google Scholar 

  53. Melmed GY, Ippoliti AF, Papadakis KA, et al.: Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101:1834–1840.

    Article  PubMed  Google Scholar 

  54. Sands BE, Cuffari C, Katz J, et al.: Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:677–692.

    Article  PubMed  Google Scholar 

  55. Peyrin-Biroulet L, Deltenre P, de Suray N, et al.: Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644–653.

    Article  CAS  PubMed  Google Scholar 

  56. Kane S, Khatibi B, Reddy D: Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008, 103:631–636.

    Article  PubMed  Google Scholar 

  57. Askling J, Brandt L, Lapidus A, et al.: Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005, 54:617–622.

    Article  CAS  PubMed  Google Scholar 

  58. Siegel CA, Marden SM, Persing SM, et al.: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874–881.

    Article  CAS  PubMed  Google Scholar 

  59. Rosh JR, Gross T, Mamula P, et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007, 13:1024–1030.

    Article  PubMed  Google Scholar 

  60. Mackey AC, Green L, Leptak C, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48:386–388.

    Article  PubMed  Google Scholar 

  61. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.

    Article  CAS  PubMed  Google Scholar 

  62. Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:542–553.

    Article  CAS  PubMed  Google Scholar 

  63. Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924.

    Article  CAS  PubMed  Google Scholar 

  64. Vermeire S, Noman M, Van Assche G, et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007, 56:1226–1231.

    Article  CAS  PubMed  Google Scholar 

  65. Vermeire S, Noman M, Van Assche G, et al.: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003, 125:32–39.

    Article  CAS  PubMed  Google Scholar 

  66. Williams EL, Gadola S, Edwards CJ: Anti-TNF-induced lupus. Rheumatology (Oxford) 2009, 48:716–720.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Calgary, 3280 Hospital Drive NW, TRW Building, Room 6D18, Calgary, Alberta, T2N 4Z6, Canada

    Cynthia H. Seow

Authors
  1. Cynthia H. Seow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shanika de Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilaad G. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shane M. Devlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Subrata Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Remo Panaccione
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia H. Seow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seow, C.H., de Silva, S., Kaplan, G.G. et al. Managing the risks of IBD therapy. Curr Gastroenterol Rep 11, 509–517 (2009). https://doi.org/10.1007/s11894-009-0077-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-009-0077-4

Keywords

Search

Navigation